<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">38638942X</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180307112109.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">161130s1989    xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1017/S0269727000010587</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">S0269727000010587</subfield>
   <subfield code="2">pii</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)cambridge-10.1017/S0269727000010587</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Growth control of normal and malignant breast epithelium</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">We review information highlighting the multiple roles of both steroidal (primarily oestrogen) and polypeptide regulators of mammary epithelial cell growth, emphasising the work of our laboratory. Effects of both classes of hormones are complex and involve multiple interactions with non-tumour, host tissue. Oestrogen may induce growth regulatory polypeptide growth factors and interact with them in hormone dependent breast cancer. Progression of hormone-dependent breast cancer to hormone independence may involve multiple genetic mechanisms of oncogene activation, loss of the oestrogen receptor, or loss of hormone responsivity of other gene products. Initial carcinogenesis and progression of mammary epithelium to cancer probably also requires both proliferative stimuli (oestrogen, polypeptide growth factors) and genetic damage, leading to qualitatively different hormonal responses (hormone responsive cancer). Future therapies should be designed to block hormonal stimulation better and to interfere with necessary activated or induced components of malignant progression such as oncogenes or polypeptide growth factors receptor systems.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Copyright © Royal Society of Edinburgh 1989</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Mechanisms and Markers of Oestrogen Action in the Breast</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Lippman</subfield>
   <subfield code="D">Marc E.</subfield>
   <subfield code="u">Lombardi Cancer Research Center, Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, DC 20007, U.S.A.</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Dickson</subfield>
   <subfield code="D">Robert B.</subfield>
   <subfield code="u">Lombardi Cancer Research Center, Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, DC 20007, U.S.A.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences</subfield>
   <subfield code="d">Royal Society of Edinburgh Scotland Foundation</subfield>
   <subfield code="g">95(1989), 89-106</subfield>
   <subfield code="x">0269-7270</subfield>
   <subfield code="q">95&lt;89</subfield>
   <subfield code="1">1989</subfield>
   <subfield code="2">95</subfield>
   <subfield code="o">PRB</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1017/S0269727000010587</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1017/S0269727000010587</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Lippman</subfield>
   <subfield code="D">Marc E.</subfield>
   <subfield code="u">Lombardi Cancer Research Center, Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, DC 20007, U.S.A</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Dickson</subfield>
   <subfield code="D">Robert B.</subfield>
   <subfield code="u">Lombardi Cancer Research Center, Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, DC 20007, U.S.A</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences</subfield>
   <subfield code="d">Royal Society of Edinburgh Scotland Foundation</subfield>
   <subfield code="g">95(1989), 89-106</subfield>
   <subfield code="x">0269-7270</subfield>
   <subfield code="q">95&lt;89</subfield>
   <subfield code="1">1989</subfield>
   <subfield code="2">95</subfield>
   <subfield code="o">PRB</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="b">CC0</subfield>
   <subfield code="u">http://creativecommons.org/publicdomain/zero/1.0</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-cambridge</subfield>
  </datafield>
 </record>
</collection>
